Current strategies in tumor-targeting

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Unknown venue

• Publication date

  2005-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/0-387-23695-3_16
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays

  2004cited by this paper
• Glucose Metabolism in Cancer

  2003cited by this paper
• Assessment of gene transfer using imaging methodology

  2003cited by this paper
• A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis

  2003cited by this paper
• Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation.

  2003cited by this paper
• Cell-penetrating Peptides

  2003cited by this paper
• In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.

  2003cited by this paper
• By-passing of P-glycoprotein Using Immunoliposomes

  2002cited by this paper
• Glufosfamide (Baxter Oncology).

  2002cited by this paper
• Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug β-D-glucosyl-ifosfamide mustard

  2002cited by this paper
• Pathways of Reductive Fragmentation of Heterocyclic Nitroarylmethyl Quaternary Ammonium Prodrugs of Mechlorethamine

  2002cited by this paper
• Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX‐GA3 in combination with a monoclonal antibody β‐glucuronidase conjugate

  2001cited by this paper
• PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.

  2001cited by this paper
• Neuroblastoma tumor cell-binding peptides identified through random peptide phage display.

  2001cited by this paper
• Liposomal encapsulated anthracyclines: new therapeutic horizons

  2001cited by this paper
• Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours

  2000cited by this paper
• Peptide analogs in the therapy of prostate cancer

  2000cited by this paper
• Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model

  2000cited by this paper
• Biodistribution and pharmacokinetics of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies

  2000cited by this paper
• Application of high-throughput screening techniques to drug discovery.

  2000cited by this paper
• Oncological applications of FDG PET imaging.

  1999cited by this paper
• Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies.

  1999cited by this paper
• Identification of receptor ligands with phage display peptide libraries.

  1999cited by this paper
• Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.

  1999cited by this paper
• Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations.

  1999cited by this paper
• Neurotensin receptors in human neoplasms: High incidence in Ewing's sarcomas

  1999cited by this paper
• Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically.

  1998cited by this paper
• Elucidation of the mechanism enabling tumor selective prodrug monotherapy.

  1998cited by this paper
• Assessment of glucosylifosfamide mustard biodistribution in rats with prostate adenocarcinomas by means of in vivo 31P NMR and in vitro uptake experiments

  1998cited by this paper
• Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1.

  1998cited by this paper
• Cell penetration by transportan.

  1998cited by this paper
• Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species 1

  1997cited by this paper
• Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.

  1997cited by this paper
• Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers

  1997cited by this paper
• Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.

  1997cited by this paper
• Application of combinatorial library methods in cancer research and drug discovery.

  1997cited by this paper
• A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus*

  1997cited by this paper
• The Cure of Childhood Leukemia: Into the Age of Miracles

  1995cited by this paper
• The third helix of the Antennapedia homeodomain translocates through biological membranes.

  1994cited by this paper
• FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models.

  1994cited by this paper
• Metabolic consequences of a reversed pH gradient in rat tumors.

  1994cited by this paper
• Antibody-Directed Enzyme Prodrug Therapy

  1994cited by this paper
• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

  1993cited by this paper
• pH in human tumour xenografts: effect of intravenous administration of glucose.

  1993cited by this paper
• The multistep nature of cancer.

  1993cited by this paper
• Use of hypoxia-directed drugs in the therapy of solid tumors.

  1992cited by this paper
• Are cancer cells acidic?

  1991cited by this paper
• The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells.

  1991cited by this paper
• Over-expression of facilitative glucose transporter genes in human cancer.

  1990cited by this paper
• Proton-mediated liberation of aldophosphamide from a nontoxic prodrug: a strategy for tumor-selective activation of cytocidal drugs.

  1989cited by this paper
• Lectin‐mediated targeting of liposomes to a model surface An ELISA method

  1988cited by this paper
• Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes.

  1987cited by this paper
• 6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity.

  1987cited by this paper
• Endocrine profile of a long-acting somatostatin derivative SMS 201-995. Study in normal volunteers following subcutaneous administration.

  1986cited by this paper
• Macromolecule-drug conjugates in targeted cancer chemotherapy.

  1984cited by this paper
• SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

  1982cited by this paper
• The evolution of therapeutic research in cancer.

  1978cited by this paper
• Inhibition of human placental-type alkaline phosphatase variants by peptides containing L-leucine.

  1977cited by this paper
• Targeting of drugs

  1977cited by this paper
• The mechanism of microsomal and mitochondrial nitroreductase. Electron spin resonance evidence for nitroaromatic free radical intermediates.

  1975cited by this paper
• Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid.

  1948cited by this paper
• The presence of high beta-glucuronidase activity in cancer tissue.

  1947cited by this paper
• THE METABOLISM OF TUMOURS

  1931cited by this paper

• Encapsulation, Release, and Cytotoxicity of Doxorubicin Loaded in Liposomes, Micelles, and Metal-Organic Frameworks: A Review

  2022cites this paper
• Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs).

  2016cites this paper
• Kidney-Specific Drug Delivery: Review of Opportunities, Achievements, and Challenges

  2016cites this paper
• Synthesis and characterization of DNA nano-meso-microspheres as drug delivery carriers for intratumoral chemotherapy

  2007cites this paper
• Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.

  2005cites this paper